These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25889635)

  • 1. Pentacycloundecane lactam vs lactone norstatine type protease HIV inhibitors: binding energy calculations and DFT study.
    Honarparvar B; Pawar SA; Alves CN; Lameira J; Maguire GE; Silva JR; Govender T; Kruger HG
    J Biomed Sci; 2015 Feb; 22(1):15. PubMed ID: 25889635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pentacycloundecane-based inhibitors of wild-type C-South African HIV-protease.
    Makatini MM; Petzold K; Sriharsha SN; Soliman ME; Honarparvar B; Arvidsson PI; Sayed Y; Govender P; Maguire GE; Kruger HG; Govender T
    Bioorg Med Chem Lett; 2011 Apr; 21(8):2274-7. PubMed ID: 21429747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, 2D-NMR and molecular modelling studies of pentacycloundecane lactam-peptides and peptoids as potential HIV-1 wild type C-SA protease inhibitors.
    Makatini MM; Petzold K; Alves CN; Arvidsson PI; Honarparvar B; Govender P; Govender T; Kruger HG; Sayed Y; JerônimoLameira ; Maguire GE; Soliman ME
    J Enzyme Inhib Med Chem; 2013 Feb; 28(1):78-88. PubMed ID: 22339087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structural studies of pentacycloundecane-based HIV-1 PR inhibitors: a hybrid 2D NMR and docking/QM/MM/MD approach.
    Makatini MM; Petzold K; Sriharsha SN; Ndlovu N; Soliman ME; Honarparvar B; Parboosing R; Naidoo A; Arvidsson PI; Sayed Y; Govender P; Maguire GE; Kruger HG; Govender T
    Eur J Med Chem; 2011 Sep; 46(9):3976-85. PubMed ID: 21741133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentacycloundecane-diol-based HIV-1 protease inhibitors: biological screening, 2D NMR, and molecular simulation studies.
    Honarparvar B; Makatini MM; Pawar SA; Petzold K; Soliman ME; Arvidsson PI; Sayed Y; Govender T; Maguire GE; Kruger HG
    ChemMedChem; 2012 Jun; 7(6):1009-19. PubMed ID: 22544389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentacycloundecane derived hydroxy acid peptides: a new class of irreversible non-scissile ether bridged type isoster as potential HIV-1 wild type C-SA protease inhibitors.
    Karpoormath R; Sayed Y; Govender P; Govender T; Kruger HG; Soliman MES; Maguire GEM
    Bioorg Chem; 2012 Feb; 40(1):19-29. PubMed ID: 21982718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interconvertions between delta-lactam and delta-lactone derivatives initiated by unique transannular interactions of the rigid cyclohexane boat structure in pentacycloundecane.
    Kruger HG; Martins FJ; Viljoen AM
    J Org Chem; 2004 Jul; 69(14):4863-6. PubMed ID: 15230619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the binding free energies of FDA approved drugs against subtype B and C-SA HIV PR: ONIOM approach.
    Sanusi ZK; Govender T; Maguire GEM; Maseko SB; Lin J; Kruger HG; Honarparvar B
    J Mol Graph Model; 2017 Sep; 76():77-85. PubMed ID: 28711760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of solvation by a generalized Born model and a self-consistent charge-density functional theory-based tight-binding method.
    Xie L; Liu H
    J Comput Chem; 2002 Nov; 23(15):1404-15. PubMed ID: 12370943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the molecular dynamics and calculated binding free energies for nine FDA-approved HIV-1 PR drugs against subtype B and C-SA HIV PR.
    Ahmed SM; Kruger HG; Govender T; Maguire GE; Sayed Y; Ibrahim MA; Naicker P; Soliman ME
    Chem Biol Drug Des; 2013 Feb; 81(2):208-18. PubMed ID: 23017010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trypanocidal activity of β-lactone-γ-lactam proteasome inhibitors.
    Steverding D; Wang X; Potts BC; Palladino MA
    Planta Med; 2012 Jan; 78(2):131-4. PubMed ID: 22034066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding Free Energy Calculations of Nine FDA-approved Protease Inhibitors Against HIV-1 Subtype C I36T↑T Containing 100 Amino Acids Per Monomer.
    Lockhat HA; Silva JR; Alves CN; Govender T; Lameira J; Maguire GE; Sayed Y; Kruger HG
    Chem Biol Drug Des; 2016 Apr; 87(4):487-98. PubMed ID: 26613568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease.
    Kar P; Lipowsky R; Knecht V
    J Phys Chem B; 2013 May; 117(19):5793-805. PubMed ID: 23614718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficiency of a second-generation HIV-1 protease inhibitor studied by molecular dynamics and absolute binding free energy calculations.
    Lepsík M; Kríz Z; Havlas Z
    Proteins; 2004 Nov; 57(2):279-93. PubMed ID: 15340915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FT-IR and FT-Raman spectroscopic signatures, vibrational assignments, NBO, NLO analysis and molecular docking study of 2-{[5-(adamantan-1-yl)-4-methyl-4H-1,2,4-triazol-3-yl]sulfanyl}-N,N-dimethylethanamine.
    Almutairi MS; Alanazi AM; Al-Abdullah ES; El-Emam AA; Pathak SK; Srivastava R; Prasad O; Sinha L
    Spectrochim Acta A Mol Biomol Spectrosc; 2015 Apr; 140():1-14. PubMed ID: 25579797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, antiviral activity, and bioavailability studies of gamma-lactam derived HIV protease inhibitors.
    Hungate RW; Chen JL; Starbuck KE; Vacca JP; McDaniel SL; Levin RB; Dorsey BD; Guare JP; Holloway MK; Whitter W
    Bioorg Med Chem; 1994 Sep; 2(9):859-79. PubMed ID: 7712123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vibrational and structural study of onopordopicrin based on the FTIR spectrum and DFT calculations.
    Chain FE; Romano E; Leyton P; Paipa C; Catalán CA; Fortuna M; Brandán SA
    Spectrochim Acta A Mol Biomol Spectrosc; 2015; 150():381-9. PubMed ID: 26057092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intriguing structure-activity relations underlie the potent inhibition of HIV protease by norstatine-based peptides.
    Tam TF; Carrière J; MacDonald D; Castelhano AL; Pliura DH; Dewdney NJ; Thomas EM; Bach C; Barnett J; Chan H
    J Med Chem; 1992 Apr; 35(7):1318-20. PubMed ID: 1560443
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors.
    Martin SF; Dorsey GO; Gane T; Hillier MC; Kessler H; Baur M; Mathä B; Erickson JW; Bhat TN; Munshi S; Gulnik SV; Topol IA
    J Med Chem; 1998 May; 41(10):1581-97. PubMed ID: 9572884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis, screening and computational investigation of pentacycloundecane-peptoids as potent CSA-HIV PR inhibitors.
    Makatini MM; Petzold K; Arvidsson PI; Honarparvar B; Govender T; Maguire GE; Parboosing R; Sayed Y; Soliman ME; Kruger HG
    Eur J Med Chem; 2012 Nov; 57():459-67. PubMed ID: 22867528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.